Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term tu [Therapeutic Use]. Found 17 abstracts

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
O'Sullivan MJ, Morrow M. Ductal carcinoma in situ--current management. Surgical Clinics of North America. 2007 Apr;87(2):333-51.
Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clinical Breast Cancer. 2006 Feb;6 Suppl 2:S36-40.
Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International Journal of Gynecological Cancer. 2005 May;15 Suppl 1:12-7.
Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Current treatment options in oncology. 2005 Mar;6(2):115-20.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Rectal cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):492-508.
Langer CJ. Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer. Clinical lung cancer. 2005 Jan;6(5):314-6, 2005 Mar.
Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Current treatment options in oncology. 2005 Nov;6(6):473-86.
Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Seminars in Nuclear Medicine. 2004 Jan;34(1 Suppl 1):4-9.
Borghaei H, Wallace SG, Schilder RJ. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clinical Lymphoma. 2004 Oct;5 Suppl 1:S16-21.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clinical lung cancer. 2004 Dec;6 Suppl 2:S85-8.
Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M, Shipley WU, Hanks GE, Sandler HM. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group trial 92-02. Journal of Clinical Oncology. 2004 Jun;22(11):2133-40.
Feigenberg SJ, Wolk KL, Yang CH, Morris CG, Zlotecki RA. Celecoxib to decrease urinary retention associated with prostate brachytherapy. Brachytherapy. 2003 Jan;2(2):103-7.
Fourkal E, Li JS, Xiong W, Nahum A, Ma CM. Intensity modulated radiation therapy using laser-accelerated protons: a Monte Carlo dosimetric study. Physics in Medicine and Biology. 2003 Dec;48(24):3977-4000.
Langer C, Damsker J, Ridge A. Reirradiation: exploring new territory in the therapy of recurrent head and neck cancer. Clinical Advances in Hematology & Oncology. 2003 Jul;1(7):424-9, 440.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term tu [Therapeutic Use]

tu [Therapeutic Use] dt [Drug Therapy] rt [Radiotherapy] Female Human 0 (Antineoplastic Agents) Antineoplastic Combined Chemotherapy Protocols Middle Aged Antineoplastic Agents aa [Analogs & Derivatives] 0 (Antineoplastic Combined Chemotherapy Protocols) pd [Pharmacology] Lung Neoplasms ae [Adverse Effects] tu [Therapeutic pa [Pathology] Survival Analysis Prognosis Male Use] Aged su [Surgery] Prostatic Neoplasms 80 and over Aged mt [Methods] Hormonal Antineoplastic Agents ai [Antagonists & Inhibitors] di [Diagnosis] me [Metabolism] sc [Secondary] Adjuvant Radiotherapy Treatment Outcome Local Neoplasm Recurrence mo [Mortality] Non-US Gov't Support Monoclonal Antibodies Adult Hormonal) 0 (Antineoplastic Agents Non-Hodgkin Lymphoma Protein Kinase Inhibitors ch [Chemistry] 0 (Protein Kinase Inhibitors) Breast Neoplasms Comparative Study Clinical Trials 10540-29-1 (Tamoxifen) Non-Small-Cell Lung Carcinoma 103882-84-4 (gemcitabine) Piperazines Proportional Hazards Models Taxoids Protein-Tyrosine Kinase 951-77-9 (Deoxycytidine) Neoplasm Staging Yttrium Radioisotopes Adjuvant Chemotherapy et [Etiology] Tamoxifen 152459-95-5 (imatinib) Pyrimidines 0 (Taxoids) Combined Modality Therapy Ovarian Neoplasms EC 2-7-1-112 (Protein-Tyrosine Kinase) 0 (Pyrimidines) Squamous Cell Carcinoma Antineoplastic) 0 (Antimetabolites pc [Prevention & Control] Radioimmunotherapy ge [Genetics] Monoclonal) 0 (Antibodies Risk Factors Antineoplastic Antimetabolites Deoxycytidine 0 (Piperazines) Camptothecin 7689-03-4 (Camptothecin) Multiple Drug Resistance 51-21-8 (Fluorouracil) Drug Dose-Response Relationship Maximum Tolerated Dose th [Therapy] im [Immunology] Interferon-alpha 0 (erlotinib) 33419-42-0 (Etoposide) Disease Progression Foreign-Body Reaction Neoplasm) 0 (DNA Follow-up studies Cisplatin Leucovorin 0 (Yttrium Radioisotopes) Polyglutamic Acid 0 (Aromatase Inhibitors) Body Burden Urinary Retention mt [Method] 0 (Imidazoles) 118072-93-8 (zoledronic acid) CD20 Antigens Liver Neoplasms 0 (cci 779) Safety ai [Antagonists & US Gov't Research Support-PHS Radiometry Biological Models Premenopause Secondary Hypertrophic Osteoarthropathy 0 (Diphosphonates) Imidazoles EC 2-7-1-37 (Protein Kinases) Lasers Non-Steroidal Anti-Inflammatory Agents 184475-35-2 (gefitinib) 0 (ibritumomab tiuxetan) Biological Availability Diphosphonates Analysis of Variance Phosphorylation Radiotherapy Dosage Rectal Neoplasms Epidermal Growth Factor Receptor Brain Neoplasms Randomized Controlled Trials US Gov't Support-PHS ci [Chemically Induced] Sulfonamides Platelet-Derived Growth Factor) EC 2-7-1-112 (Receptors Kidney Neoplasms Quinazolines ad [Administration & Dosage] Gastrointestinal Stromal Tumors US Gov't Support-Non-PHS Fluorouracil Phytogenic Antineoplastic Agents Predictive Value of Tests 0 (Interferon-alpha) Protons North America Ribonucleotide Reductases Neoplasm DNA Algorithms Computer-Assisted Radiotherapy Planning Conformal Radiotherapy Biological Tumor Markers Lymphatic Metastasis Carcinoma in Situ Second Primary Neoplasms
Last updated on Wednesday, February 05, 2020